Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer

This publication has 32 references indexed in Scilit:

• Leuprorelin Acetate Every-3-Months Depot Versus Cyclophosphamide, Methotrexate, and Fluorouracil As Adjuvant Treatment in Premenopausal Patients With Node-Positive Breast Cancer: The TABLE Study
  Journal of Clinical Oncology, 2007
• What do we know about the mechanisms of aromatase inhibitor resistance?
  The Journal of Steroid Biochemistry and Molecular Biology, 2006
• Critical Appraisal of Primary Systemic Endocrine Therapy in Receptor-Positive Postmenopausal Breast Cancer: An Update
  Oncology Research and Treatment, 2006
• Changes in oestrogen receptor-α and -β during progression to acquired resistance to tamoxifen and fulvestrant (Faslodex, ICI 182,780) in MCF7 human breast cancer cells
  The Journal of Steroid Biochemistry and Molecular Biology, 2006
• Recommendations From an International Expert Panel on the Use of Neoadjuvant (Primary) Systemic Treatment of Operable Breast Cancer: An Update
  Journal of Clinical Oncology, 2006
• Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole
  British Journal of Cancer, 2006
• Prognostic Value of Pathologic Complete Response After Primary Chemotherapy in Relation to Hormone Receptor Status and Other Factors
  Journal of Clinical Oncology, 2006
• Failure to Achieve Castration Levels in Patients Using Leuprolide Acetate in Locally Advanced Prostate Cancer
  European Urology, 2006
• Clinical significance of estrogen receptor β in breast cancer
  Cancer Chemotherapy and Pharmacology, 2005
• Estrogen-receptor-directed neoadjuvant therapy for breast cancer: Results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy
  Annals of Oncology, 2001